NCT01516060View on ClinicalTrials.gov

The Neurocognitive Sub-study of Encore1

PHASE3CompletedINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

HIV

Interventions

DRUG

Efavirenz

400mg qd; 2 x 200mg

DRUG

Efavirenz

600mg qd; 3 x 200mg qd

Trial Locations (1)

Unknown

HIVNAT Research Collaboration, Bangkok

Sponsors

Lead Sponsor

Kirby Institute

All Listed Sponsors

collaborator

The HIV Netherlands Australia Thailand Research Collaboration

OTHER

lead

Kirby Institute

OTHER_GOV

NCT01516060 - The Neurocognitive Sub-study of Encore1 | Biotech Hunter | Biotech Hunter